What can epigenomics tell us about prostate cancer disparities?
Epigenomics · 03.10.2026 · 18 (10) · 1189-1192
DOI: 10.1080/17501911.2026.2745488 ↗Kurz gefasst
Editorial in der Zeitschrift Epigenomics, online erschienen am 11.10.2026. Verfasst von Carmen Ortiz-Sánchez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Sciences, Ponce Research Institute, Ponce Health Sciences University, Ponce, Puerto Rico. Die Arbeit nennt 19 Literaturangaben. Gefördert von: NCI NIH HHS, U54 PHSU-MCC Partnership.
Abstract (Originalsprache)
1. Prostate cancer is the second most commonly diagnosed cancer among men worldwide, with approximately 1.47 million new cases reported in 2022 [1]. However, this burden is not distributed equally ...
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Basic Sciences, Ponce Research Institute, Ponce Health Sciences University, Ponce, Puerto Rico.
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Förderung
- NCI NIH HHS
- U54 PHSU-MCC Partnership
Zitieren
APA
Ortiz-Sánchez, C., & Park, J. Y. (2026). What can epigenomics tell us about prostate cancer disparities?. Epigenomics, 18(10), 1189-1192. https://doi.org/10.1080/17501911.2026.2745488
Vancouver
Ortiz-Sánchez C, Park JY. What can epigenomics tell us about prostate cancer disparities?. Epigenomics. 2026;18(10):1189-1192. doi:10.1080/17501911.2026.2745488
BibTeX
@article{OrtizSnchez2026,
author = {Ortiz-Sánchez, Carmen and Park, Jong Y},
title = {What can epigenomics tell us about prostate cancer disparities?},
journal = {Epigenomics},
year = {2026},
volume = {18},
number = {10},
pages = {1189--1192},
doi = {10.1080/17501911.2026.2745488}
}
EUVIMED